Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

The Impact of Progressive Visual Field Constriction on Reading Ability in an Inherited Retinal Degeneration.

Jolly JK, Couldridge-Smith CE, Xue K, MacLaren RE.

Ophthalmologica. 2019 Nov 5:1-10. doi: 10.1159/000503294. [Epub ahead of print]

PMID:
31689706
2.

Comment on: 'Sector retinitis pigmentosa caused by mutations of the RHO gene'.

Orlans HO, MacLaren RE.

Eye (Lond). 2019 Oct 28. doi: 10.1038/s41433-019-0648-z. [Epub ahead of print] No abstract available.

PMID:
31659286
3.

Presence of corneal crystals confirms an unusual presentation of Bietti's retinal dystrophy.

Song WK, Clouston P, MacLaren RE.

Ophthalmic Genet. 2019 Oct 22:1-5. doi: 10.1080/13816810.2019.1678176. [Epub ahead of print]

PMID:
31638456
4.

Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice.

Jolly JK, Bridge H, MacLaren RE.

Front Pharmacol. 2019 Sep 18;10:1076. doi: 10.3389/fphar.2019.01076. eCollection 2019. Review.

5.

RPGR gene therapy presents challenges in cloning the coding sequence.

Martinez-Fernandez De La Camara C, Cehajic-Kapetanovic J, MacLaren RE.

Expert Opin Biol Ther. 2019 Oct 20:1-9. doi: 10.1080/14712598.2020.1680635. [Epub ahead of print]

PMID:
31612744
6.

Validation of electronic visual acuity (EVA) measurement against standardised ETDRS charts in patients with visual field loss from inherited retinal degenerations.

Jolly JK, Juenemann K, Boagey H, Nadsady M, Bridge H, Maclaren RE.

Br J Ophthalmol. 2019 Oct 4. pii: bjophthalmol-2019-315124. doi: 10.1136/bjophthalmol-2019-315124. [Epub ahead of print]

PMID:
31585961
7.

Molecular Therapies for Choroideremia.

Cehajic Kapetanovic J, Barnard AR, MacLaren RE.

Genes (Basel). 2019 Sep 23;10(10). pii: E738. doi: 10.3390/genes10100738. Review.

8.

Retinal stem cell transplantation: Balancing safety and potential.

Singh MS, Park SS, Albini TA, Canto-Soler MV, Klassen H, MacLaren RE, Takahashi M, Nagiel A, Schwartz SD, Bharti K.

Prog Retin Eye Res. 2019 Sep 5:100779. doi: 10.1016/j.preteyeres.2019.100779. [Epub ahead of print] Review.

9.

Molecular Strategies for RPGR Gene Therapy.

Cehajic Kapetanovic J, McClements ME, Martinez-Fernandez de la Camara C, MacLaren RE.

Genes (Basel). 2019 Sep 4;10(9). pii: E674. doi: 10.3390/genes10090674. Review.

10.

Clinical Characterization of Retinitis Pigmentosa Associated With Variants in SNRNP200.

Yusuf IH, Birtel J, Shanks ME, Clouston P, Downes SM, Charbel Issa P, MacLaren RE.

JAMA Ophthalmol. 2019 Sep 5. doi: 10.1001/jamaophthalmol.2019.3298. [Epub ahead of print]

PMID:
31486839
11.

Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial.

Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, Reichel FFL, Kuehlewein L, Kahle NA, Peters T, Girach A, Zrenner E, Ueffing M, MacLaren RE, Bartz-Schmidt KU, Wilhelm B.

JAMA Ophthalmol. 2019 Aug 29. doi: 10.1001/jamaophthalmol.2019.3278. [Epub ahead of print]

PMID:
31465092
12.

A Specific Macula-Predominant Retinal Phenotype Is Associated With the CDHR1 Variant c.783G>A, a Silent Mutation Leading to In-Frame Exon Skipping.

Charbel Issa P, Gliem M, Yusuf IH, Birtel J, Müller PL, Mangold E, Downes SM, MacLaren RE, Betz C, Bolz HJ.

Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3388-3397. doi: 10.1167/iovs.18-26415.

PMID:
31387115
13.

Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration.

Davis JL, Gregori NZ, MacLaren RE, Lam BL.

Retina. 2019 Oct;39 Suppl 1:S2-S8. doi: 10.1097/IAE.0000000000002609. No abstract available.

PMID:
31335483
14.

Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model.

Halioua-Haubold CL, Jolly JK, Smith JA, Pinedo-Villanueva R, Brindley DA, MacLaren RE.

Eye (Lond). 2019 Aug;33(8):1215-1223. doi: 10.1038/s41433-019-0492-1. Epub 2019 Jul 17.

PMID:
31312000
15.

Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues.

Chandler LC, Barnard AR, Caddy SL, Patrício MI, McClements ME, Fu H, Rada C, MacLaren RE, Xue K.

Mol Ther Methods Clin Dev. 2019 Jun 4;14:77-89. doi: 10.1016/j.omtm.2019.05.012. eCollection 2019 Sep 13.

16.

Filtration of Short-Wavelength Light Provides Therapeutic Benefit in Retinitis Pigmentosa Caused by a Common Rhodopsin Mutation.

Orlans HO, Merrill J, Barnard AR, Charbel Issa P, Peirson SN, MacLaren RE.

Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2733-2742. doi: 10.1167/iovs.19-26964.

PMID:
31247114
17.

Clinical and Molecular Characterization of PROM1-Related Retinal Degeneration.

Cehajic-Kapetanovic J, Birtel J, McClements ME, Shanks ME, Clouston P, Downes SM, Charbel Issa P, MacLaren RE.

JAMA Netw Open. 2019 Jun 5;2(6):e195752. doi: 10.1001/jamanetworkopen.2019.5752.

18.

Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage.

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, MacLaren RE, Querques G, Fauser S, Hoyng CB, Downes SM, Boon CJF.

Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1419-1425. doi: 10.1007/s00417-019-04333-y. Epub 2019 May 23.

PMID:
31123815
19.
20.

A Randomized Crossover Study to Assess the Usability of Two New Vision Tests in Patients with Low Vision.

Jolly JK, Gray JM, Salvetti AP, Han RC, MacLaren RE.

Optom Vis Sci. 2019 Jun;96(6):443-452. doi: 10.1097/OPX.0000000000001380.

PMID:
31058709
21.

A Quantitative Chloride Channel Conductance Assay for Efficacy Testing of AAV.BEST1.

Wood SR, McClements ME, Martinez-Fernandez de la Camara C, Patrício MI, Uggenti C, Sekaran S, Barnard AR, Manson FD, MacLaren RE.

Hum Gene Ther Methods. 2019 Apr;30(2):44-52. doi: 10.1089/hgtb.2018.267.

PMID:
30963787
22.

Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S, Downes SM, Hoyng CB, Boon CJF.

Am J Ophthalmol. 2019 Sep;205:1-10. doi: 10.1016/j.ajo.2019.03.025. Epub 2019 Apr 3.

PMID:
30951686
23.

Reply.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF.

Ophthalmology. 2019 Apr;126(4):e30-e31. doi: 10.1016/j.ophtha.2018.11.005. No abstract available.

PMID:
30910048
24.

Re: Song et al., Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. Hum Gene Ther Clin Dev 2018; 29(4):188-197.

MacLaren RE, Fischer MD, De La Camara CM.

Hum Gene Ther Clin Dev. 2019 Mar;30(1):40. doi: 10.1089/humc.2019.29041.rem. No abstract available.

PMID:
30888916
25.

Changes in microchip position after implantation of a subretinal vision prosthesis in humans.

Kuehlewein L, Troelenberg N, Stingl K, Schleehauf S, Kusnyerik A, Jackson TL, MacLaren RE, Chee C, Roider J, Wilhelm B, Gekeler F, Bartz-Schmidt KU, Zrenner E, Stingl K.

Acta Ophthalmol. 2019 Sep;97(6):e871-e876. doi: 10.1111/aos.14077. Epub 2019 Feb 28.

PMID:
30816625
26.

The Location of Exon 4 Mutations in RP1 Raises Challenges for Genetic Counseling and Gene Therapy.

Nanda A, McClements ME, Clouston P, Shanks ME, MacLaren RE.

Am J Ophthalmol. 2019 Jun;202:23-29. doi: 10.1016/j.ajo.2019.01.027. Epub 2019 Feb 4.

PMID:
30731082
27.

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review.

Meinert E, Alturkistani A, Osama T, Halioua-Haubold CL, Car J, Majeed A, Wells G, MacLaren RE, Brindley D.

JMIR Res Protoc. 2019 Feb 7;8(2):e10705. doi: 10.2196/10705.

28.

AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization.

Hughes CP, O'Flynn NMJ, Gatherer M, McClements ME, Scott JA, MacLaren RE, Goverdhan S, Glennie MJ, Lotery AJ.

Mol Ther Methods Clin Dev. 2018 Nov 22;13:86-98. doi: 10.1016/j.omtm.2018.11.005. eCollection 2019 Jun 14.

29.

Near-Infrared Autofluorescence in Choroideremia: Anatomic and Functional Correlations.

Birtel J, Salvetti AP, Jolly JK, Xue K, Gliem M, Müller PL, Holz FG, MacLaren RE, Charbel Issa P.

Am J Ophthalmol. 2019 Mar;199:19-27. doi: 10.1016/j.ajo.2018.10.021. Epub 2018 Oct 26.

PMID:
30713139
30.

Atypical choroideremia presenting with early-onset macular atrophy.

Kontos G, Kwan J, Xue K, Patrício MI, Clouston P, Packham E, MacLaren RE, Downes SM.

Acta Ophthalmol. 2019 Sep;97(6):633-636. doi: 10.1111/aos.14025. Epub 2019 Jan 28.

PMID:
30690895
31.

Unilateral pigmentary retinopathy: a retrospective case series.

Errera MH, Robson AG, Wong T, Hykin PG, Pal B, Sagoo MS, Pavesio CE, Moore AT, Webster AR, MacLaren RE, Holder GE.

Acta Ophthalmol. 2019 Jun;97(4):e601-e617. doi: 10.1111/aos.13981. Epub 2018 Dec 31.

PMID:
30597758
32.

A Novel Achromatopsia Mouse Model Resulting From a Naturally Occurring Missense Change in Cngb3.

Hassall MM, Barnard AR, Orlans HO, McClements ME, Charbel Issa P, Aslam SA, MacLaren RE.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):6102-6110. doi: 10.1167/iovs.18-24328.

PMID:
30592498
33.

A detailed in vivo analysis of the retinal nerve fibre layer in choroideremia.

Fu DJ, Xue K, Jolly JK, MacLaren RE.

Acta Ophthalmol. 2019 Jun;97(4):e589-e600. doi: 10.1111/aos.13973. Epub 2018 Dec 21.

PMID:
30575280
34.

Exploring the Variable Phenotypes of RPGR Carrier Females in Assessing their Potential for Retinal Gene Therapy.

Nanda A, Salvetti AP, Clouston P, Downes SM, MacLaren RE.

Genes (Basel). 2018 Dec 18;9(12). pii: E643. doi: 10.3390/genes9120643.

35.

Reply.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Keunen JEE, Groenewoud JMM, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF.

Ophthalmology. 2019 Jan;126(1):e11. doi: 10.1016/j.ophtha.2018.06.038. Epub 2018 Nov 22. No abstract available.

PMID:
30470545
36.

Electrophysiological verification of enhanced S-cone syndrome caused by a novel c.755T>C NR2E3 missense variant.

Cehajic-Kapetanovic J, Cottriall CL, Jolly JK, Shanks M, Clouston P, Charbel Issa P, MacLaren RE.

Ophthalmic Genet. 2019 Feb;40(1):29-33. doi: 10.1080/13816810.2018.1547912. Epub 2018 Nov 23.

PMID:
30466340
37.

An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4-/- Mice.

McClements ME, Barnard AR, Singh MS, Charbel Issa P, Jiang Z, Radu RA, MacLaren RE.

Hum Gene Ther. 2019 May;30(5):590-600. doi: 10.1089/hum.2018.156. Epub 2018 Dec 24.

PMID:
30381971
38.

CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA.

Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, Reichel FFL, Kuehlewein L, Kahle NA, Peters T, Girach A, Zrenner E, Ueffing M, MacLaren RE, Bartz-Schmidt K, Wilhelm B.

Retina. 2018 Oct 9. doi: 10.1097/IAE.0000000000002360. [Epub ahead of print]

PMID:
30308560
39.

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia.

Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP, Patrício MI, Edwards TL, Groppe M, Orlans HO, Tolmachova T, Black GC, Webster AR, Lotery AJ, Holder GE, Downes SM, Seabra MC, MacLaren RE.

Nat Med. 2018 Oct;24(10):1507-1512. doi: 10.1038/s41591-018-0185-5. Epub 2018 Oct 8.

PMID:
30297895
40.

Macular spatial distribution of preserved autofluorescence in patients with choroideremia.

Hariri AH, Ip MS, Girach A, Lam BL, Fischer MD, Sankila EM, Pennesi ME, Holz FG, Maclaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Stepien KE, Larsen M, Gorin MB, Meunier I, Webster AR, Sadda S; For Natural History of the Progression of Choroideremia (NIGHT) Study Group.

Br J Ophthalmol. 2019 Jul;103(7):933-937. doi: 10.1136/bjophthalmol-2018-312620. Epub 2018 Oct 8.

PMID:
30297337
41.

Optimisation of dark adaptation time required for mesopic microperimetry.

Han RC, Gray JM, Han J, Maclaren RE, Jolly JK.

Br J Ophthalmol. 2019 Aug;103(8):1092-1098. doi: 10.1136/bjophthalmol-2018-312253. Epub 2018 Sep 29.

PMID:
30269100
42.

First-in-human study of the safety and viability of intraocular robotic surgery.

Edwards TL, Xue K, Meenink HCM, Beelen MJ, Naus GJL, Simunovic MP, Latasiewicz M, Farmery AD, de Smet MD, MacLaren RE.

Nat Biomed Eng. 2018 Jun 18;2:649-656. doi: 10.1038/s41551-018-0248-4.

43.

Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results.

Lam BL, Davis JL, Gregori NZ, MacLaren RE, Girach A, Verriotto JD, Rodriguez B, Rosa PR, Zhang X, Feuer WJ.

Am J Ophthalmol. 2019 Jan;197:65-73. doi: 10.1016/j.ajo.2018.09.012. Epub 2018 Sep 19.

PMID:
30240725
44.

Gene therapy for the treatment of X-linked retinitis pigmentosa.

Martinez-Fernandez De La Camara C, Nanda A, Salvetti AP, Fischer MD, MacLaren RE.

Expert Opin Orphan Drugs. 2018 Feb 27;6(3):167-177. doi: 10.1080/21678707.2018.1444476.

45.

Stem Cell Treatment for Age-Related Macular Degeneration: the Challenges.

Singh MS, MacLaren RE.

Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD78-AMD82. doi: 10.1167/iovs.18-24426. Review. No abstract available.

PMID:
30025109
46.

Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience.

Dimopoulos IS, Hoang SC, Radziwon A, Binczyk NM, Seabra MC, MacLaren RE, Somani R, Tennant MTS, MacDonald IM.

Am J Ophthalmol. 2018 Sep;193:130-142. doi: 10.1016/j.ajo.2018.06.011. Epub 2018 Jun 27.

PMID:
29940166
47.

Choroideremia: molecular mechanisms and development of AAV gene therapy.

Patrício MI, Barnard AR, Xue K, MacLaren RE.

Expert Opin Biol Ther. 2018 Jul;18(7):807-820. doi: 10.1080/14712598.2018.1484448. Epub 2018 Jun 22. Review.

PMID:
29932012
48.

Olfactory Dysfunction in Patients With CNGB1-Associated Retinitis Pigmentosa.

Charbel Issa P, Reuter P, Kühlewein L, Birtel J, Gliem M, Tropitzsch A, Whitcroft KL, Bolz HJ, Ishihara K, MacLaren RE, Downes SM, Oishi A, Zrenner E, Kohl S, Hummel T.

JAMA Ophthalmol. 2018 Jul 1;136(7):761-769. doi: 10.1001/jamaophthalmol.2018.1621.

49.

Slowly progressive retinitis pigmentosa caused by two novel mutations in the MAK gene.

Gray JM, Orlans HO, Shanks M, Clouston P, MacLaren RE.

Ophthalmic Genet. 2018 Aug;39(4):508-511. doi: 10.1080/13816810.2018.1474369. Epub 2018 May 21.

PMID:
29781741
50.

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF.

Ophthalmology. 2018 Oct;125(10):1547-1555. doi: 10.1016/j.ophtha.2018.04.021. Epub 2018 Jun 14.

Supplemental Content

Loading ...
Support Center